Substitution of factor XIII: a therapeutic approach to ulcerative colitis

Haemostasis. 1991;21(1):5-9. doi: 10.1159/000216195.

Abstract

Three patients with ulcerative colitis in the active stage demonstrated reduced levels of F XIII activity and F XIII subunit A (61 and 80.3%, respectively). Because of the lack of clinical improvement during conservative therapy, the patients were treated additionally with F XIII concentrate (Fibrogammin HS, Behring, FRG) for 10 days. The substitution resulted in an increase in F XIII activity (144.3%) and F XIII subunit A (238%) as well as in a marked improvement in symptoms.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Blood Coagulation Disorders / blood
  • Blood Coagulation Disorders / etiology
  • Blood Coagulation Disorders / therapy*
  • Colitis, Ulcerative / complications*
  • Colitis, Ulcerative / drug therapy
  • Factor XIII / analysis
  • Factor XIII / therapeutic use*
  • Factor XIII Deficiency
  • Female
  • Gastrointestinal Hemorrhage / etiology
  • Gastrointestinal Hemorrhage / therapy*
  • Humans
  • Male
  • Metronidazole / therapeutic use
  • Middle Aged
  • Sulfasalazine / therapeutic use

Substances

  • Adrenal Cortex Hormones
  • Metronidazole
  • Sulfasalazine
  • Factor XIII